Engineering human mesenchymal stem cells to release adenosine using miRNA technology.
Adenosine is an important modulator of metabolic activity with powerful tissue- and cell-protective functions. Adenosine kinase (ADK), the major adenosine-regulating enzyme, is critical to adapt its intra- and extra-cellular levels in response to environmental changes. Lentiviral RNAi-mediated down-regulation of ADK in human mesenchymal stem cells (hMSCs) has therefore been considered an effective tool for engineering therapeutically effective adenosine-releasing cell grafts that could constitute patient-identical autologous implants for clinical application. We constructed lentiviral vectors that coexpress miRNA directed against ADK and an emerald green fluorescent protein (EmGFP) reporter gene. Following lentiviral transduction of hMSCs, we demonstrated up to 80% down-regulation of ADK and 98% transduction efficiency. Transduced hMSCs continued to express EmGFP after 4-6 consecutive passages and EmGFP-positive hMSC grafts survived in the hippocampal fissure of mouse brains and provided efficient adenosine-dependent neuroprotection in a mouse model of seizure-induced cell loss.
Ren
Gaoying
G
Department of Medicine, University of Washington, Seattle, WA, USA.
Boison
Detlev
D
D000241:Adenosine / Q000378:metabolism*; D000248:Adenosine Kinase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D004195:Disease Models, Animal; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008297:Male; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000235:genetics*; D034622:RNA Interference / Q000502:physiology; D012640:Seizures / Q000473:pathology / Q000628:therapy
D035683:MicroRNAs; D000248:Adenosine Kinase; D000241:Adenosine